Postprint version. Published in International Journal of Obesity and Related Metabolic Disorders, Volume 31, Issue 9, September 1, 2007, pages 1442-1448.
NOTE: At the time of publication, the author Suzanne Phelan was not yet affiliated with Cal Poly.
The definitive version is available at https://doi.org/10.1038/sj.ijo.0803606.
To evaluate the effects of weight loss on the risk of having metabolic syndrome after 1 year of treatment with lifestyle modification alone, pharmacotherapy alone (sibutramine) or the combination of the two.
Randomized, controlled, 1-year clinical trial.
One hundred and eighty women and 44 men, 18–65 years of age, with a body mass index of 30–45 kg/m2, free of uncontrolled hypertension or type 1 or 2 diabetes.
Fifteen milligrams of sibutramine per day alone, lifestyle modification counseling alone, sibutramine plus lifestyle modification counseling or sibutramine plus brief lifestyle modification counseling.
The metabolic syndrome, as defined by the Adult Treatment Panel III.
Before treatment, 34.8% of the participants had the metabolic syndrome. Metabolic syndrome was more prevalent in Caucasians than African Americans (42.5 vs 20.3%; P44 years) than younger (less than or equal to44 years) participants (47.5 vs 20.8%; PConclusions:
The metabolic syndrome was prevalent in over one-third of obese individuals who sought weight loss treatment, and the prevalence differed by age, sex and ethnicity. Moderate weight loss markedly reduced the odds of metabolic syndrome in this sample.
2007 Nature Publishing Group.